Biomarkers in Alzheimer’s disease: new frontiers with olfactory models
Inflammopharmacology · 2025-05 · 33 (5) · 2623-2640
DOI: 10.1007/s10787-025-01705-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Inflammopharmacology, online erschienen am 01.05.2025. Verfasst von Shubhrat Maheshwari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology…. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 116 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD), the leading cause of dementia worldwide, presents a significant diagnostic challenge, as clinical diagnoses are often made at advanced stages when neurodegenerative damage is already extensive. The study of biomarkers is necessary for improving identification, prognosis, and disease monitoring. Current research has primarily focused on cerebrospinal fluid and imaging biomarkers, including amyloid-β (Aβ1-42), phosphorylated tau, and total tau. However, these methods are invasive, expensive, and not widely accessible. Emerging approaches aim to identify novel, cost-effective, and minimally invasive biomarkers, particularly from blood-based and other peripheral sources. This review explores the role of olfactory neuronal precursors (ONPs) derived from the olfactory neuroepithelium (ONE) as a promising and innovative model for biomarker discovery in AD. ONPs can be non-invasively obtained directly from patients, offering a unique resource to study AD-related pathophysiological mechanisms. These neuronal lineage cells exhibit characteristics that make them a reliable surrogate model for central nervous system studies, enabling the evaluation of established biomarkers and facilitating the identification of novel candidates. Additionally, we discuss the potential of ONPs to enhance clinical practice through their accessibility and suitability for high-throughput biomarker analysis. By integrating the study of ONPs with existing biomarker research, this review highlights new frontiers in the quest to refine diagnostic tools and advance our understanding of Alzheimer's disease, paving the way for innovative strategies in early detection and personalized management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, 211007, India.
- Department of Pharmacy, Faculty of Pharmacy, Integral University, Lucknow, 226026, Uttar Pradesh, India.
- Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, 211007, India. amita.verma@shiats.edu.in.
Zitieren
APA
Maheshwari, S., Singh, A., & Verma, A. (2025). Biomarkers in Alzheimer’s disease: new frontiers with olfactory models. Inflammopharmacology, 33(5), 2623-2640. https://doi.org/10.1007/s10787-025-01705-1
Vancouver
Maheshwari S, Singh A, Verma A. Biomarkers in Alzheimer’s disease: new frontiers with olfactory models. Inflammopharmacology. 2025;33(5):2623-2640. doi:10.1007/s10787-025-01705-1
BibTeX
@article{Maheshwari2025,
author = {Maheshwari, Shubhrat and Singh, Aditya and Verma, Amita},
title = {Biomarkers in Alzheimer’s disease: new frontiers with olfactory models},
journal = {Inflammopharmacology},
year = {2025},
volume = {33},
number = {5},
pages = {2623--2640},
doi = {10.1007/s10787-025-01705-1}
}
EUVIMED